Oncology

Code Test Genes TAT
8824 CancerNext®
APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, GREM1, HOXB13, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RECQL, SMAD4, SMARCA4, STK11, TP53 14-21 days
9510 CustomNext-Cancer®
AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, EGFR, EGLN1, EPCAM, FAM175A, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PALLD, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 14-21 days
8855 BRCANext™
ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53 14-21 days
8860 BRCANext-Expanded
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53 14-21 days
8845 ProstateNext®
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53 14-21 days
8822 ColoNext®
APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 14-21 days
8836 BRCAplus®
ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53 7-10 days
9811 TumorNext-HRD®
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C, RAD51D 3-4 weeks
8980 TumorNext-Lynch
BRAF, EPCAM, KRAS, MLH1, MSH2, MSH6, NRAS, PMS2 3-4 weeks
8838 BRCA1/2 seq and del/dup
BRCA1, BRCA2 6-10 days
8042 PancNext®
APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 14-21 days
8064 PancNext® plus Pancreatitis
APC, ATM, BRCA1, BRCA2, CASR, CDKN2A, CFTR, CPA1, CTRC, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, SPINK1, STK11, TP53 14-21 days
8517 HNPCC concurrent
EPCAM, MLH1, MSH2, MSH6, PMS2 14-21 days
3040 APC seq and del/dup
Adenomatous polyposis
Familial adenomatous polyposis (FAP)
APC 14-21 days
4661 MUTYH seq and del/dup
Adenomatous polyposis
MUTYH-associated polyposis (MAP)
MUTYH 14-21 days
5900 RenalNext®
BAP1, CHEK2, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL 14-21 days
8702 Microsatellite instability (MSI) analysis
3-4 weeks
8874 CancerNext-Expanded®
AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNA1, DICER1, EGFR, EGLN1, EPCAM, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RECQL, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 14-21 days
8847 BrainTumorNext®
AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, EPCAM, LZTR1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, POT1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL 14-21 days
5504 PGLNext®
EGLN1, FH, KIF1B, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL 14-21 days
8849 MelanomaNext®
BAP1, BRCA2, CDK4, CDKN2A, MITF, POT1, PTEN, RB1, TP53 14-21 days
9014 ATM seq and del/dup
ATM 14-21 days
9044 BAP1 seq and del/dup BAP1 14-21 days
8604 BMPR1A & SMAD4 seq and del/dup
BMPR1A, SMAD4 14-21 days
4726 CDH1 seq and del/dup
CDH1 14-21 days
4708 CDKN2A & CDK4 seq and del/dup CDK4, CDKN2A 14-21 days
9016 CHEK2 seq and del/dup
CHEK2 14-21 days
5260 DICER1 seq and del/dup
DICER1 14-21 days
8519 HNPCC/Lynch del/dup EPCAM, MLH1, MSH2 7-14 days
6301 FH seq and del/dup
FH 14-21 days
5921 FLCN seq and del/dup
FLCN 14-21 days
2646 MEN1 seq and del/dup
MEN1 14-21 days
9046 MITF specific site analysis MITF 7-14 days
8508 MLH1 seq and del/dup
MLH1 14-21 days
9004 MRE11A seq and del/dup MRE11A 14-21 days
8510 MSH2 seq & del/dup & EPCAM del/dup
EPCAM, MSH2 14-21 days
8512 MSH6 seq and del/dup
MSH6 14-21 days
5704 NF1 seq and del/dup
NF1 14-21 days
9024 NF2 seq and del/dup
NF2 14-21 days
2366 PALB2 seq and del/dup
PALB2 14-21 days
4646 PMS2 seq and del/dup
PMS2 14-21 days
5684 PTCH1 seq and del/dup
PTCH1 14-21 days
2106 PTEN seq and del/dup
PTEN 14-21 days
5426 RB1 seq and del/dup
RB1 14-21 days
2680 RET seq
Multiple endocrine neoplasia type 2 (MEN2) and familial medullary thyroid cancer (FMTC)
RET-related Hirschsprung disease
RET 14-21 days
7180 SMARCB1 seq and del/dup
SMARCB1 14-21 days
2766 STK11 seq and del/dup
STK11 14-21 days
2866 TP53 seq and del/dup
TP53 14-21 days
5904 TSC1/2 seq and del/dup
TSC1, TSC2 14-21 days
2606 VHL seq and del/dup
VHL 14-21 days

Please select a category to find your test or learn more about our highlighted tests below

  • Highlighted Tests
    • why choose ambry

      Ambry places significant value on implementing new lab processes designed to increase quality, and advancing technology across the field with innovative approaches. Our ongoing participation in numerous research studies and collaborations is so that we can better assess clinical validity of gene-disease relationships. This is to ensure that the results healthcare providers receive are as accurate and informative as possible. That’s why we led the largest study of its kind (20,000 cases) guiding us on additional confirmatory testing when we saw specific well-defined thresholds, reducing the chance of delivering a false positive patient report or one that misses real mutations (Mu et al., November 2016). The more accurate the reports, the more insight healthcare providers will have to treat their patients.

      Choose from one of our more frequently ordered tests listed below.

      CancerNext®

      When finding the answer is critical for guiding your patient’s healthcare, CancerNext is a comprehensive 36-gene panel that identifies inherited risks for at least 8 types of cancers, giving you more information to make better treatment and management decisions.

      CustomNext-Cancer®

      For patients with a complex personal or family history of cancer, CustomNext gives you the flexibility to choose which genes to analyze so you can accurately diagnose, treat, and manage your patient’s cancer risks.

      BRCANext™

      Management guidelines-based panel including 18 genes associated with hereditary breast and/or gynecologic cancers.

      BRCANext-Expanded

      BRCANext-Expanded is a 23 gene panel associated with hereditary breast and/or gynecologic cancers.

      ProstateNext®

      Since hereditary prostate cancer is not well understood or often recognized, clinicians need clear results to guide treatment decisions. ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer.

      ColoNext®

      Patients with a suspicious personal or family history of colorectal cancer or polyps benefit from early detection and cancer prevention. Identify patients with an increased risk by using ColoNext, a 20-gene panel designed to provide more precise data to help guide personalized medical management recommendations such as earlier or more frequent colonoscopies.

      BRCAplus®

      To understand your patient’s risk and minimize uncertain results, you need a genetic test designed specifically for patients with a high risk personal and/or family breast cancer history. BRCAplus tests critical breast cancer genes with published guidelines for medical management, so you can help your patient make confident, personalized screening and prevention decisions.

      TumorNext-HRD®

      TumorNext-HRD clearly determines patients who may benefit from treatment with PARP inhibitors in one simple test. It simultaneously understands hereditary risk as it detects and differentiates between germline and somatic mutations in homologous recombination repair genes including BRCA1 and BRCA2.

      TumorNext-Lynch

      When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy, you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.

  • Breast
  • Gastrointestinal
  • Gynecologic
  • Urologic
  • Tumor Testing
    • Tumor Testing

      Testing Options

      Name TAT Genes
      TumorNext-HRD® 3-4 weeks 11
      TumorNext-Lynch 3-4 weeks 8
      Microsatellite instability (MSI) analysis 3-4 weeks 0
  • Comprehensive
    • Comprehensive

      Comprehensive Testing

      Name TAT Genes
      CustomNext-Cancer® 14-21 days 91
      CancerNext-Expanded® 14-21 days 77
      CancerNext® 14-21 days 36
  • Other
    • Other

      Other Hereditary Cancer Testing Options

      Name TAT Genes
      BrainTumorNext® 14-21 days 29
      PGLNext® 14-21 days 14
      MelanomaNext® 14-21 days 9
  • Single Gene
    • Single Gene

      Single gene testing options

      Name TAT
      APC gene sequence and deletion/duplication analysis 14-21 days
      ATM gene sequence and deletion/duplication analysis 14-21 days
      BAP1 gene sequence and deletion/duplication analysis 14-21 days
      BRCA1/BRCA2 gene sequence and deletion/duplication analysis 6-10 days
      BMPR1A/SMAD4 gene sequence and deletion/duplication analysis 14-21 days
      CDH1 gene sequence and deletion/duplication analysis 14-21 days
      CDKN2A/CDK4 gene sequence and deletion/duplication analysis 14-21 days
      CHEK2 gene sequence and deletion/duplication analysis 14-21 days
      DICER1 gene sequence and deletion/duplication analysis 14-21 days
      EPCAM deletion/duplication analysis 7-14 days
      FH gene sequence and deletion/duplication analysis 14-21 days
      FLCN gene sequence and deletion/duplication analysis 14-21 days
      MEN1 gene sequence and deletion/duplication analysis 14-21 days
      MITF specific site analysis 7-14 days
      MLH1 gene sequence and deletion/duplication analysis 14-21 days
      MRE11A gene sequence and deletion/duplication analysis 14-21 days
      MSH2 gene sequence and deletion/duplication analysis, MSH2 inversion analysis, and EPCAM deletion/duplication analysis 14-21 days
      MSH6 gene sequence and deletion/duplication analysis 14-21 days
      MUTYH gene sequence and deletion/duplication analysis 14-21 days
      NF1 gene sequence and deletion/duplication analysis 14-21 days
      NF2 gene sequence and deletion/duplication 14-21 days
      PALB2 gene sequence and deletion/duplication analysis 14-21 days
      PMS2 gene sequence and deletion/duplication analysis 14-21 days
      PTCH1 gene sequence and deletion/duplication analysis 14-21 days
      PTEN gene sequence and deletion/duplication analysis 14-21 days
      RB1 gene sequence and deletion/duplication analysis 14-21 days
      RET gene sequence 14-21 days
      SMARCB1 gene sequence and deletion/duplication 14-21 days
      STK11 gene sequence and deletion/duplication analysis 14-21 days
      TP53 gene sequence and deletion/duplication analysis 14-21 days
      TSC1/TSC2 gene sequence and deletion/duplication analysis 14-21 days
      VHL gene sequence and deletion/duplication analysis 14-21 days

Search Results

Start your search...